Performance of RCUS Arcus Biosciences | -22.7% in 12m
Compare RCUS with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Arcus Biosciences with its related Sector/Index XBI
Performance Duell RCUS vs XBI
| TimeFrame | RCUS | XBI |
|---|---|---|
| 1 Day | -2.79% | 0.34% |
| 1 Week | -9.11% | -2.66% |
| 1 Month | 0.26% | 4.22% |
| 3 Months | -18.2% | -12.21% |
| 6 Months | 10.7% | 22.07% |
| 12 Months | -22.7% | 7.23% |
| YTD | -20.4% | -1.22% |
| Rel. Perf. 1m | -0.24 | |
| Rel. Perf. 3m | -0.81 | |
| Rel. Perf. 6m | -0.67 | |
| Rel. Perf. 12m | -2.71 |
Is Arcus Biosciences a good stock to buy?
No, based on ValueRay Fundamental Analyses, Arcus Biosciences (NYSE:RCUS) is currently (May 2024)
a stock to sell. It has a ValueRay Fundamental Rating of -58.46 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RCUS as of May 2024 is 13.63. This means that RCUS is currently overvalued and has a potential downside of -13.02% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RCUS as of May 2024 is 13.63. This means that RCUS is currently overvalued and has a potential downside of -13.02% (Sold with Premium).
Is RCUS a buy, sell or hold?
- Strong Buy: 8
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
Values above 0%: RCUS is performing better - Values below 0%: RCUS is underperforming
Compare RCUS with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -8.82% | -3.61% | -6.56% | -50.58% |
| US NASDAQ 100 | QQQ | -9.96% | -5.96% | -7.52% | -54.88% |
| US Dow Jones Industrial 30 | DIA | -6.56% | -1.14% | 0.03% | -42.43% |
| German DAX 40 | DBXD | -8.89% | -2.53% | -5.56% | -39.22% |
| UK FTSE 100 | ISFU | -7.76% | -3.37% | -2.81% | -40.04% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -6.84% | 1.66% | 10.30% | -16.34% |
| Hongkong Hang Seng | HSI | -6.33% | -5.41% | 9.03% | -16.55% |
| Japan Nikkei 225 | EXX7 | -8.44% | 0.35% | -0.12% | -31.96% |
| India NIFTY 50 | INDA | -9.77% | -1.70% | -7.00% | -51.01% |
| Brasil Bovespa | EWZ | -5.80% | 4.51% | 18.48% | -33.43% |
RCUS Arcus Biosciences vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -9.53% | -4.68% | -7.41% | -57.36% |
| Consumer Discretionary | XLY | -7.21% | 2.98% | 7.01% | -38.01% |
| Consumer Staples | XLP | -7.02% | -0.62% | 0.65% | -31.13% |
| Energy | XLE | -7.44% | 4.49% | -0.25% | -45.16% |
| Financial | XLF | -6.67% | -0.70% | -7.01% | -53.14% |
| Health Care | XLV | -6.66% | -1.34% | -0.20% | -37.08% |
| Industrial | XLI | -7.34% | 0.70% | -6.80% | -49.97% |
| Materials | XLB | -7.73% | -0.56% | -2.56% | -45.15% |
| Real Estate | XLRE | -5.58% | -0.45% | 7.66% | -30.05% |
| Technology | XLK | -9.78% | -7.42% | -6.68% | -54.17% |
| Utilities | XLU | -7.13% | -6.21% | -4.67% | -37.50% |
| Aerospace & Defense | XAR | -7.76% | -3.84% | -3.05% | -51.53% |
| Biotech | XBI | -6.45% | -3.96% | -11.33% | -29.89% |
| Homebuilder | XHB | -5.86% | 1.04% | -16.30% | -71.28% |
| Retail | XRT | -8.84% | -2.34% | -7.18% | -52.74% |
Does Arcus Biosciences outperform its market, is RCUS a Sector Leader?
No, over the last 12 months Arcus Biosciences (RCUS) made -22.66%, while its related Sector, the SPDR S&P Biotech (XBI) made 7.23%.
Over the last 3 months RCUS made -18.17%, while XBI made -12.21%.
No, over the last 12 months Arcus Biosciences (RCUS) made -22.66%, while its related Sector, the SPDR S&P Biotech (XBI) made 7.23%.
Over the last 3 months RCUS made -18.17%, while XBI made -12.21%.
| Period | RCUS | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 0.26% | 4.22% | 3.87% |
| 3 Months | -18.17% | -12.21% | 4.98% |
| 12 Months | -22.66% | 7.23% | 27.92% |